London, UK – [Insert Date] – In a significant stride forward for patients battling debilitating mitochondrial disorders, Pretzel Therapeutics announced today that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for a clinical trial of its novel therapeutic candidate, PX578. This pivotal approval paves the way for a Phase II study to investigate PX578’s potential to modify the course of POLG-mediated primary mitochondrial disorders, a group of rare and progressive genetic conditions for which no approved treatments currently exist. The company anticipates initiating this crucial trial by the close of 2026.
n
This latest regulatory endorsement from the MHRA represents the third substantial milestone for PX578 in recent months, underscoring the rapid and promising progression of this investigational therapy. The journey towards this point has been marked by significant achievements, including the US Food and Drug Administration’s (FDA) clearance of an investigational new drug (IND) application in August 2026, followed by the prestigious Fast Track designation for the treatment of POLG-mediated primary mitochondrial disorders in September. These successive approvals signal a strong belief in PX578’s therapeutic potential from leading global regulatory bodies.
n
A Timeline of Progress: Paving the Way for PX578
n
The path to this critical Phase II trial has been meticulously charted, demonstrating a clear and accelerating trajectory for PX578. The initial regulatory hurdle was cleared in the United States with the FDA’s IND clearance in August 2026. This authorization signifies that the FDA has reviewed the preclinical and manufacturing data for PX578 and concluded that it is safe enough to proceed with human clinical trials. Following this crucial step, the FDA further acknowledged the urgent need and potential impact of PX578 by granting it Fast Track designation in September 2026.
n
Fast Track is a designation granted by the FDA to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. This designation allows for more frequent communication with the FDA throughout the drug development process, including meetings to discuss the drug’s development plan and clinical trial design. It also makes the drug eligible for priority review and accelerated approval if it meets the necessary criteria.
n
The recent MHRA authorization in the UK now allows Pretzel Therapeutics to commence its Phase II clinical trial in a key European market. This dual regulatory progress in both the US and UK highlights the global commitment to advancing treatments for rare genetic disorders and the robust data package supporting PX578’s development. The company’s strategic approach to seeking regulatory approvals across major markets demonstrates a clear intent to make this potential therapy accessible to a broad patient population as swiftly as possible.
n
Understanding POLG-Mediated Mitochondrial Disorders: A Dire Unmet Need
n
POLG-mediated primary mitochondrial disorders represent a significant and often devastating group of rare genetic conditions. These disorders arise from mutations in the POLG gene, which encodes for the catalytic subunit of mitochondrial DNA polymerase gamma. This enzyme is absolutely essential for the replication and maintenance of mitochondrial DNA (mtDNA), the genetic material found within mitochondria, the powerhouses of the cell.
n
Mitochondria are responsible for generating the vast majority of a cell’s energy through cellular respiration. When mtDNA is not replicated or maintained properly due to POLG dysfunction, cellular energy production is severely compromised. This energy deficit can manifest in a wide range of symptoms, affecting organs and tissues with high energy demands, such as the brain, muscles, heart, and liver.
n
The clinical presentation of POLG disorders is highly variable and can include neurological impairments like epilepsy, ataxia, developmental delay, and cognitive decline; muscular weakness and fatigue; ophthalmological issues; and gastrointestinal problems. The progressive nature of these disorders means that symptoms often worsen over time, leading to significant disability and reduced life expectancy.
n
Crucially, there are currently no approved therapies that directly address the underlying cause of POLG-mediated mitochondrial disorders. Existing treatments are largely supportive, aiming to manage symptoms and improve quality of life, but they do not halt or reverse the disease progression. This stark reality underscores the profound unmet medical need that PX578 aims to address.
n
PX578: A Novel Approach to Restoring Mitochondrial Function
n
PX578 is a small molecule therapeutic candidate designed with a specific and innovative mechanism of action. It is engineered to activate the POLG enzyme, thereby stimulating the replication and repair of mitochondrial DNA. By increasing mtDNA levels, PX578 aims to restore mitochondrial function and enhance cellular energy production.
n
The company describes PX578 as a central nervous system (CNS)-penetrant molecule. This characteristic is particularly important for treating mitochondrial disorders, as neurological symptoms are common and can be severe. A CNS-penetrant drug has the ability to cross the blood-brain barrier, allowing it to reach and exert its therapeutic effects within the brain, where mitochondria play a critical role in neuronal function.
n
The overarching goal of PX578 is to not only improve mitochondrial activity but also to potentially modify the underlying disease process of POLG disorders. By targeting the root cause of mtDNA depletion, PX578 offers the hope of slowing or even reversing disease progression, a prospect that has been elusive for patients and their families to date.
n
Preclinical and Phase I Data: A Foundation of Promise
n
The progression of PX578 into Phase II clinical trials is supported by a robust foundation of preclinical and early-stage human data. Extensive preclinical investigations, utilizing a diverse array of in vitro and in vivo models, have provided compelling evidence of PX578’s disease-modifying capabilities. These studies have demonstrated the drug’s ability to enhance POLG activity and increase mtDNA levels in relevant cellular and animal models of POLG disorders.
n
Furthermore, a recently concluded Phase I study involving healthy volunteers has provided critical safety and tolerability data for PX578. Phase I trials are primarily designed to assess the safety of a new drug, determine a safe dosage range, and identify side effects. The successful completion of this phase, demonstrating an acceptable safety profile in humans, is a prerequisite for advancing to larger efficacy studies. The positive outcomes from these early-stage investigations have been instrumental in substantiating the potential of PX578 and building confidence for its progression into more advanced clinical trials.
n
The POLARIS Trial: A Rigorous Evaluation of Efficacy
n
The upcoming Phase II study, aptly named the POLg Activation and Recovery In Subjects (POLARIS) trial, is designed as a randomized, double-blind, placebo-controlled study. This rigorous trial design is considered the gold standard for evaluating the efficacy and safety of new treatments.
n
- n
- Randomized: Participants will be randomly assigned to receive either PX578 or a placebo. This randomization helps to ensure that the groups are comparable at the start of the study, minimizing bias.
- Double-blind: Neither the participants nor the researchers administering the treatment will know who is receiving PX578 and who is receiving the placebo. This blinding prevents expectations from influencing the results.
- Placebo-controlled: A placebo is an inactive substance that looks identical to the study drug. Comparing the effects of PX578 to a placebo allows researchers to determine if the observed effects are due to the drug itself or other factors.
n
n
n
n
The POLARIS trial will enroll adult patients diagnosed with POLG disease. The primary objectives of the study will be to meticulously assess PX578’s tolerability and safety profile, understand its pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug), evaluate its pharmacodynamics (how the drug affects the body and its biological targets), and, crucially, determine its clinical efficacy in improving outcomes for patients with POLG disease. The findings from the POLARIS trial will be pivotal in determining the future development path of PX578, including its potential for regulatory approval and widespread clinical use.
n
Official Responses and Future Outlook
n
Jay Parrish, Chairman and CEO of Pretzel Therapeutics, expressed his enthusiasm and the significance of these regulatory achievements. "Receiving UK authorisation following FDA clearance of our IND represents an important milestone for PX578 and for our efforts to bring a potential disease-modifying treatment to people living with POLG-mediated mitochondrial disorders," he stated. "We are encouraged by the continued progress and are committed to advancing PX578 through rigorous clinical evaluation to address the significant unmet needs of these patients."
n
The authorization of the PX578 clinical trial by the MHRA is more than just a regulatory step; it is a beacon of hope for individuals and families affected by POLG-mediated mitochondrial disorders. The rarity of these conditions often means that research and drug development face significant challenges. However, the focused efforts of companies like Pretzel Therapeutics, coupled with supportive regulatory pathways, are crucial for bringing life-changing therapies to fruition.
n
The successful completion of the POLARIS trial could herald a new era in the management of POLG disorders, offering the first treatment that targets the underlying cause of the disease. The implications extend beyond this specific condition, potentially informing the development of therapies for other mitochondrial disorders and highlighting the potential of targeting mitochondrial dysfunction as a therapeutic strategy for a broader range of diseases. As the trial progresses, the global scientific and patient communities will be watching closely, anticipating the dawn of a new therapeutic paradigm.
